Zobrazeno 61 - 70
of 340
pro vyhledávání: ''
Autor:
Koji Haratani, Yoshikane Nonagase, Hisato Kawakami, Kazuhiko Nakagawa, Ryoji Kato, Naoki Takegawa, Hidetoshi Hayashi, Osamu Maenishi, Junji Tsurutani, Masayuki Takeda, Kimio Yonesaka
Publikováno v:
International Journal of Cancer. 145:3414-3424
Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an unmet clinical need for the treatment of tumors that express HER2 protein in the absence of HE
Publikováno v:
International Journal of Cancer. 144(10):2365-2376
Chemotherapy‐induced gastrointestinal toxicity (CIGT) occurs in up to 80% of all patients undergoing cancer treatment, and leads to symptoms such as diarrhoea, abdominal bleeding and pain. There is currently limited understanding of how to predict
Autor:
Takeshi Terashima, Noriho Iida, Jun Seishima, Shuichi Kaneko, Tatsuya Yamashita, Kuniaki Arai, Eishiro Mizukoshi
Publikováno v:
International Journal of Cancer
Overuse of antibiotic drugs alters the composition of gut microbiota and has detrimental effects on the host. In our study, we investigated association of gut flora and antibiotics in the prognosis of patients with liver cancer who have undergone che
Autor:
János Tibor Fekete, Balázs Győrffy
Publikováno v:
International Journal of Cancer. 145:3140-3151
Systemic therapy of breast cancer can include chemotherapy, hormonal therapy and targeted therapy. Prognostic biomarkers are able to predict survival and predictive biomarkers are able to predict therapy response. In this report, we describe the init
Autor:
Heiko Graf, Bernhard Volz, Matthias W. Beckmann, Bernhard Martin, Christian M. Bayer, Achim Rody, Alexander Fridman, Christoph Thomssen, CB Walter, Andreas D. Hartkopf, Tanja Fehm, Felix Heindl, Rachel Wuerstlein, Volker Schulz, Sara Y. Brucker, Brigitte Rack, Peter A. Fasching, Christian R. Loehberg, Dieter Steinfeld-Birg, Tobias Brodkorb, Hans-Christian Kolberg, Wolfram Malter, Katrin Almstedt, Carolin C. Hack, Lothar Häberle, G. Baake, Petra Krabisch, Nicolai Maass, Sherko Kuemmel, Volker Pelzer, Christoph Lindner, Paul Gass, C. Wolf, Michael Weigel, A. Kohls, Michael P. Lux, Claudia Rauh, C Brucker, Oliver Hoffmann, Wolfgang Janni, Naiba Nabieva, Nadia Harbeck, Alexander Hein, G. Fischer
Publikováno v:
International Journal of Cancer. 145:2114-2121
One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-
Autor:
Thorsten Kühn, Volkmar Müller, Isabel Ben-Batalla, Miguel Cubas-Cordova, Tanja Fehm, Michael Untch, Thomas Karn, Benjamin Schnappauf, Melanie Janning, Victoria Gensch, Christian Schem, Brigitte Rack, Carsten Bokemeyer, Friedrich Overkamp, Sonja Loges, K Kittel, Petra Krabisch, Eik Vettorazzi, Gunter von Minckwitz, Klaus Pantel, Marianne Just, Mahdi Rezai, Carsten Denkert, Sibylle Loibl, Peter A. Fasching, Hans Tesch, Frank Holms, Christine Eulenburg
Publikováno v:
International Journal of Cancer. 145:857-868
We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme-linked immunosorbent assay (ELISA). Corre
Autor:
Matthias D'hooghe, Olivier De Wever, Sophie Goethals, Pascal de Tullio, Jonas Steenbrugge, Silke Geurs, Rob De Vreese, Alien Laevens, Yves Depetter, Elien Vandoorn, Marc Bracke, Evelyne Meyer
Publikováno v:
International Journal of Cancer. 145:735-747
Our study investigates the biochemical and functional impact of selective histone deacetylase 6 (HDAC6) inhibitors, a promising class of novel therapeutics, in several cancer models. Selective HDAC6 inhibitors (Tubathian A, Tubastatin A, Tubacin and
Autor:
Yingqi Hua, Wei Sun, Zhuoying Wang, Min Mao, Zongyi Wang, Weilin Sang, Tao Zhang, Zhengdong Cai, Mengxiong Sun, Dongqing Zuo, Jing Xu, Yafei Jiang, Zifei Zhou, Zhenfeng Duan, Gangyang Wang, Chongren Wang, Zeze Fu, Hongsheng Wang, Fei Yin
Publikováno v:
International Journal of Cancer. 145:979-993
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with highly aggressive behavior and early systemic metastasis. The survival rates for osteosarcoma remain unchanged over the past two decades. Studies aiming to
Autor:
Aron Popovtzer, Manu Prasad, Jonathan Zorea, José Baselga, Limor Cohen, Raphael Pelossof, Matthew G. Fury, Fabiola Cecchi, Ben-Zion Joshua, Liz Cohen, Ofra Novoplansky, Nora Katabi, Maurizio Scaltriti, Ksenia M. Yegodayev, Moshe Elkabets
Publikováno v:
International Journal of Cancer. 145:748-762
An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET pathway a
Autor:
Yuan Yuan Chen, Rui Sun, Xiao Chang Gong, Ping Ai, Xing Lai Feng, Guoqing Hu, Guo Xian Long, Wen Fei Li, Ying Sun, Xiang Ying Xu, Ning Zhang, Ling Guo, Jin Gao Li, Yan Ping Mao, Xiao Zhong Chen, Bao Min Zheng, Ling Li, Shao Bo Liang, Jian Yu Xu, Ying Guo, Jun Ma, Ling Long Tang, Fang Yun Xie, Li Lin, Meng Zhong Liu, Fan Zhang, Lei Chen, Nian Yong Chen, Yu Ming Chen, Chun Ying Shen, Hao Yuan Mo, Xiao-Dong Zhu, Chaosu Hu, Wei Han Hu, Yan Sun
Publikováno v:
International Journal of Cancer. 145:295-305
To report long-term results of a randomized controlled trial that compared cisplatin/fluorouracil/docetaxel (TPF) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in locoregionally advanced nasopharyngeal carcinoma